{
Matthew Weston

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV

ubs upgrades astrazeneca to buy with target raised to 14200 pence

UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising the price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's significant pipeline potential, estimating an additional $17.6 billion in revenue by 2030 if late-stage candidates succeed, with 2025 being pivotal for seven key drug results.
@borsen_news
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
Finance & Economy, Market Report
07:07 13.02.2025

ubs downgrades novartis shares amid patent expirations and market challenges

UBS has downgraded Novartis shares from Buy to Neutral, lowering the target price from CHF 111 to CHF 104, citing concerns over upcoming patent expirations that could slow growth. Despite a strong product portfolio and solid financial health, the company faces challenges that may impact its stock performance beyond mid-2025. Additionally, Novartis is nearing EU antitrust approval for its $16.5 billion acquisition of Catalent, which aims to enhance its manufacturing capabilities.
Investing.com Deutsch
United States Dollar Euro Swiss Franc Novartis AG CHE Matthew Weston Show more
Business & Industry, Market Report
07:04 13.02.2025

ubs upgrades astrazeneca to buy raises price target to 142 gbp

UBS has upgraded AstraZeneca shares to a Buy rating, raising the price target from GBP 115.00 to GBP 142.00, citing the company's strong market position and robust sales growth forecasts. AstraZeneca's diversified pipeline and solid fundamentals, including an 82% gross margin, support this positive outlook. Other financial institutions, like BofA Securities and Morgan Stanley, also maintain optimistic ratings, highlighting the potential for significant developments in the coming months.
Investing.com Deutsch
British Pound Sterling AstraZeneca PLC USA GBR Matthew Weston
Business & Industry, Market Report
07:01 13.02.2025

ubs upgrades astrazeneca to buy with target raised to 14200 pence

UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising its price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's significant pipeline potential, projecting an additional $17.6 billion in sales by 2030, contingent on successful late-stage drug trials. Key results from seven new drugs are expected in 2025, marking a pivotal year for the firm.
aktiencheck.de
United States Dollar Euro AstraZeneca PLC CHE GBR Matthew Weston
Finance & Economy, Market Report
06:46 13.02.2025

ubs downgrades novartis to neutral with price target of chf104

UBS analyst Matthew Weston has downgraded Novartis (NOVN:SW) (NYSE: NVS) from Buy to Neutral, setting a new price target of CHF 104.00. This change reflects a shift in the firm's outlook on the pharmaceutical giant as of February 13, 2025.
StreetInsider.com
Swiss Franc Novartis AG CHE Matthew Weston
Finance & Economy, Market Report
06:15 13.02.2025

UBS maintains neutral rating for AstraZeneca after mixed quarterly results

UBS has maintained a "Neutral" rating for AstraZeneca, setting a target price of 11,500 pence following the release of quarterly figures. While product sales exceeded consensus estimates by 2%, the company's core EBIT fell short of market forecasts, according to analyst Matthew Weston.
boerse.de
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
Finance & Economy, Market Report
12:01 06.02.2025

ubs maintains neutral rating for astrazeneca with target price of 11500 pence

UBS has maintained a 'Neutral' rating for AstraZeneca, setting a target price of 11,500 pence following the release of quarterly figures. While product sales exceeded consensus estimates by 2%, the company's core EBIT fell short of market forecasts. As of February 6, 2025, AstraZeneca's stock was trading at €141.95, reflecting a 5.74% increase.
aktiencheck.de
British Pound Sterling AstraZeneca PLC DEU GBR Matthew Weston
Finance & Economy, Market Report
11:01 06.02.2025

ubs upgrades novartis to buy with target price of 111 francs

UBS has upgraded Novartis to a 'Buy' rating with a target price of 111 Swiss francs, following a review of the company's strong quarterly results. Analyst Matthew Weston has adjusted his estimates accordingly, reflecting confidence in Novartis' performance.
boerse.de
Swiss Franc Novartis AG CHE Matthew Weston Thomas Müller
Finance & Economy, Market Report
12:50 03.02.2025

ubs maintains buy rating for novartis with target of 111 francs

UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 Swiss francs. Analyst Matthew Weston has adjusted his estimates following the company's strong quarterly results released on Monday.
MarketScreener
Swiss Franc Novartis AG CHE Matthew Weston
Finance & Economy, Market Report
11:50 03.02.2025

ubs maintains buy rating for novartis with price target of 111 francs

UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs. Analyst Matthew Weston highlighted the company's strong results in a recent study published on January 31, 2025.
boerse.de
Swiss Franc Novartis AG CHE Matthew Weston
Finance & Economy, Market Report
11:37 31.01.2025
Trending
Subcategory
Corporate News Industry Trends Stock Market Updates Retail and Consumer Goods Global Financial Events Finance Mergers & Acquisitions Global Trade Developments Industry Mergers & Acquisitions Central Bank Actions CEO Changes Banking Regulations Supply Chain Management Startups & Entrepreneurship Energy Sector Developments AI Innovations Government Economic Policies Workplace Trends Cryptocurrency Trends Market Analysis and Predictions Emerging Startups
Countries:
USA CHN GBR IND CHE CAN JPN FRA DEU MEX RUS SGP BRA ZAF AUT ARE SAU ITA IDN IRL
Companies:
The Goldman Sachs Group, Inc. Bank of America Corporation Alphabet Inc. Apple Inc. Barclays PLC Tesla, Inc. Wells Fargo & Company Citigroup Inc. Deutsche Bank RV Global PP Commerzbank AG Lloyds Banking Group plc PepsiCo, Inc. BNP Paribas SA Google Inc. NVIDIA Corporation UBS Group AG Wix.com Ltd. BP Castrol K.K. Valvoline Inc. Bosch Limited
Currencies:
United States Dollar Euro Chinese Yuan British Pound Sterling Swiss Franc Indian Rupee Japanese Yen Indonesian Rupiah Canadian Dollar Russian Ruble South Korean Won United Arab Emirates Dirham Offshore Chinese Yuan Ghanaian Cedi Hungarian Forint Albanian Lek Brazilian Real Singapore Dollar Qatari Riyal Jordanian Dinar
People:
Donald Trump Elon Musk Warren Buffett Sergey Brin Larry Page Goldman Sachs Kelvin Taylor Carsten Fritsch Christopher Chandler Scott Bessent Martin Schlegel Jerome Powell Kubra Khan Joe Biden Volkmar Baur Christopher Wallerstedt Brian Moynihan Airlangga Hartarto Francesco Gaetano Caltagirone Leonardo Del Vecchio

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.